Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Mantle-Cell 4Lymphoma 3Waldenstrom Macroglobulinemia 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Mature B-Cell Malignancies 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Hematologic Neoplasms 1Hematologic Diseases 1B-cell Malignancies 1

Interventions

fludarabine 6trametinib 5Specimen Handling 5Standard of Care 4Practice Guidelines as Topic 4Magnetic Resonance Spectroscopy 4fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3Melphalan 3Interviews as Topic 3GSK2636771 3Cyclophosphamide 3Crizotinib 3Busulfan 3Biopsy 3Antilymphocyte Serum 3AP 1903 reagent 3venetoclax 2thymoglobulin 2palbociclib 2osimertinib 2letermovir 2dabrafenib 2capivasertib 2binimetinib 2adavosertib 2X-Rays 2Thiotepa 2Tacrolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hematologic Neoplasms × zanubrutinib × Clear all
NCT06697184 2025-12-17

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

BeOne Medicines

Phase 1/2 Active not recruiting
56 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡